Emerging drugs for diabetic foot ulcers
Emerging drugs for diabetic foot ulcers
Authors: Petrova, Nina1; Edmonds, Michael2
Source: Expert Opinion on Emerging Drugs, Volume 11, Number 4, November 2006 , pp. 709-724(16)
Publisher: Informa Healthcare
IngentaConnect
Abstract:
Diabetic foot ulceration results from factors extrinsic to the foot such as repeated trauma, ischaemia and infection, as well as intrinsic factors that lead to impairment of wound healing. Intrinsic factors are less well understood, but include deficiency of growth factors, changes in extracellular matrix components with excess proteases, reduced fibroblast activity, cellular abnormalities, deficiencies of angiogenesis, nitric oxide abnormalities and hyperglycaemia. The scientific rationale of therapy is to correct both the external factors that cause diabetic foot ulcers and the internal factors that lead to impairment of wound healing. Current research is leading to new therapies that can be divided into the following classes: growth factors, skin substitutes, extracellular matrix proteins, stem cell therapy, gene therapy, protease inhibitors, angiogenesis stimulants, nitric oxide-releasing agents, adenosine agonists, immunostimulants, vasoactive compounds and granulating agents. These therapies should be considered when existing treatments to correct extrinsic factors have failed to heal ulceration in the diabetic foot.
Keywords: diabetic foot ulcer; growth factors; skin substitutes; wound healing
Document Type: Research article
DOI: 10.1517/14728214.11.4.709
Affiliations: 1: 1Research Fellow, King's College Hospital, Diabetic Foot Clinic, London SE5 9RS, UK 2: 2Consultant Physician, King's College Hospital, Diabetic Foot Clinic, London SE5 9RS, UK., Email: Michael.Edmonds@kingsch.nhs.uk
* Website © 2009 Ingenta. Article copyright remains with the publisher, society or author(s) as specified within the article
This article may be viewed in its entirety by purchase at the website.
